Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots... Show more
PEN is expected to report earnings to rise 67.05% to $1.47 per share on February 23
Q4'26
Est.
$1.47
Q2'26
Missed
by $0.28
Q1'26
Missed
by $0.25
Q4'25
Beat
by $0.08
Q3'25
Beat
by $0.04
The last earnings report on July 30 showed earnings per share of 87 cents, missing the estimate of $1.16. With 360.03K shares outstanding, the current market capitalization sits at 12.78B.